Biogen
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of BIIB would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (1991) — listing | $1,786,900 34.1× | $2,581,734 33.9× |
| Year 6 (1996) | $323,238 7.0× | $469,401 7.0× |
| Year 11 (2001) | $83,337 2.2× | $121,180 2.2× |
| Year 16 (2006) | $50,395 1.6× | $73,302 1.6× |
| Year 21 (2011) | $21,656 0.9× | $31,518 0.9× |
| Year 26 (2016) | $12,912 0.8× | $18,776 0.8× |
| Year 31 (2021) | $7,663 0.9× | $11,151 0.9× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Headquarters
Cambridge, Massachusetts, United States
Popular scenarios with BIIB
For illustration only — not investment advice. Past performance is not indicative of future results.